Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
What will members gain?

Download Now: New Slide Deck Programme

Slide decks focusing on key results and expert analysis from FOURIER and ODYSSEY OUTCOMES – two landmark trials in PCSK9 inhibition.

Find out more »

Most viewed

Hot Topics

News from the 10th Expert Meeting of the Editorial Board of PCSK9 Education and Research Forum
Treatment Guidelines: Now and the Future
Professor Henry Ginsberg (University of Columbia, New York, USA): The 2018 AHA/ACC Treatment Guidelines: Key learnings
Watch Webcast

Professor Børge Nordestgaard (University of Copenhagen, Denmark): Lipoprotein(a): a therapeutic target in guidelines?
Watch Webcast

From the Editors

LDL cholesterol goals in patients with diabetes – How low?

Professor Derick Raal, University of the Witwatersrand, Johannesburg, South Africa
Do we need to treat LDL cholesterol more aggressively in diabetes patients, especially those with a history of ACS? A new analysis from ODYSSEY OUTCOMES lends support to this approach.
Read the report


ACC 2017

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology